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ABSTRACT: Human nonlysosomal glucosylceramidase
(GBA2) is one of several enzymes that controls levels of
glycolipids and whose activity is linked to several human disease
states. There is a major need to design or discover selective
GBA2 inhibitors both as chemical tools and as potential
therapeutic agents. Here, we describe the development of a
ﬂuorescence polarization activity-based protein proﬁling
(FluoPol-ABPP) assay for the rapid identiﬁcation, from a
350+ library of iminosugars, of GBA2 inhibitors. A focused
library is generated based on leads from the FluoPol-ABPP
screen and assessed on GBA2 selectivity oﬀset against the other glucosylceramide metabolizing enzymes, glucosylceramide
synthase (GCS), lysosomal glucosylceramidase (GBA), and the cytosolic retaining β-glucosidase, GBA3. Our work, yielding
potent and selective GBA2 inhibitors, also provides a roadmap for the development of high-throughput assays for identifying
retaining glycosidase inhibitors by FluoPol-ABPP on cell extracts containing recombinant, overexpressed glycosidase as the easily
accessible enzyme source.
■ INTRODUCTION
Human neutral glucosylceramidase (GBA2, nonlysosomal
glucocerebrosidase), a member of the glycoside hydrolase
(GH) family, GH116 (www.cazy.org), hydrolyzes glucosylcer-
amide in the cytosol to produce glucose and ceramide.1−3
GBA2 is located at the cytosolic leaﬂet of the endoplasmic
reticulum, Golgi apparatus, and endosomes.1,4 GBA2 controls
levels of glucosylceramide, which is synthesized at the cytosolic
leaﬂet of the Golgi apparatus prior to translocation to the
lumen of the organelle for elongation to complex glyco-
sphingolipids. GBA2 activity is complementary to GH30
human acid glucosylceramidase (GBA, glucocerebrosidase),
which processes glucosylceramide in lysosomes.5 Genetic
mutations in GBA are at the basis of the lysosomal storage
disorder Gaucher disease. Gaucher macrophages are loaded
with massive amounts of glucosylceramide.5 Other tissues in
Gaucher, however, have remarkably normal glucosylceramide
levels, and it is likely that GBA2 can compensate for reduced
GBA activity in these tissues.5 Glucosylceramide has been
linked to inﬂammation as well,6 underscoring the biomedical
potential of compounds able to modulate glucosylceramide
levels.
In addition to its interplay with GBA, GBA2 is itself
implicated in many diseases. Mutations in the GBA2 gene cause
hereditary spastic paraplegia and autosomal recessive cerebellar
ataxia,7−9 indicating that compounds able to enhance GBA2
activity could have therapeutic potential. Conversely, com-
pounds able to (partially) block GBA2 activity also hold
therapeutic value; we recently found that lowering GBA2
activity in Niemann-Pick type C (NPC) mouse models led to
elongated life-span and improved motor coordination.10 This
ﬁnding we correlated to correction of GBA2 activity levels in
Purkinje cells, which are among the most aﬀected neuronal cells
in NPC. Slowing-down of neuropathological processes in NPC
mice was achieved by genetic ablation of the GBA2 gene and
alternatively by pharmacological inhibition of the gene product,
the latter with N-alkyldeoxynojirimycin derivatives such as N-
buty ldeoxynoj i r imycin or N -(5)-adamantane-1-y l -
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methoxypentyl deoxynojirimycin (respectively Zavesca (1) and
AMP-DNM (2), Figure 1).10 Indeed, we and others have
reported on the development of N-alkyldeoxynojirimycin
derivatives as potent GBA2 inhibitors. The most potent
GBA2 inhibitor at present is AMP-DNM (2), with a Ki of
about 3 nM; this compound however also inhibits glucosylcer-
amide synthase (GCS) and GBA at high nanomolar
concentrations.11,12
GBA2 inhibitors thus have considerable potential both as
cellular probes/tools and as therapeutic agents. Often, though,
potent GBA2 inhibitors have signiﬁcant oﬀ-targets; not only
promiscuity toward GBA but also the enzyme responsible for
the biosynthesis of glucosylceramide: GCS. Selective in vivo
GBA2 inhibition is therefore complicated. For this reason, and
considering the pharmaceutical potential of GBA2 as a drug
target, selective GBA2 inhibitors are desirable commodities.
Similarly, in order to access speciﬁc inhibitors, there is an
urgent need for assays that rapidly identify potential GBA2
inhibitors. We here report on the development of a
ﬂuorescence polarization activity-based protein-proﬁling (Fluo-
Pol-ABPP) assay for fast identiﬁcation of GBA2 inhibitors in
extracts from cells overexpressing GBA2. Screening of our
iminosugar library, which contains over 350 entries, provided
lead structures bearing a relatively small (compared to existing
nanomolar GBA2 inhibitors, including 2 and 3) apolar head
groups. Building a focused library around this theme and
assessment of the inhibitory potential of these against GBA2,
GBA, and GCS yielded new leads for, and new insights into,
future development of potent, selective GBA2 inhibitors. These
leads, combined with our FluoPol-ABPP assay, are a useful
addition to existing reagents and tools in unraveling GBA2
functioning in health and disease.
■ RESULTS AND DISCUSSION
Our FluoPol-ABPP assay is based on our activity-based
glycosidase proﬁling methodology that capitalizes on the two-
step double displacement mechanism employed by retaining
glycosidases. N-Alkylcyclophellitol aziridines, with the aziridine
nitrogen bearing reporter groups (ﬂuorophores, biotin), are in
class, broad-spectrum retaining β-glucosidase activity-based
probes (ABPs) reporting on GBA, GBA2, and the cytosolic
retaining β-glucosidase GBA3 in human tissue (Figure 1A).13
In order to support speciﬁc reaction and covalency, we solved
the structure of the Thermoanaerobacterium xylanolyticum
TxGH116 β-glucosidase, a close homologue of human GBA2
with a conserved active site, in complex with cyclophellitol
aziridine 5 (the precursor of ABP 4) to ascertain that
cyclophellitol aziridines react with the active site nucleophile
and thus that competitors of ABP 4 are true active site
inhibitors, Figure 1B.14 The aziridine indeed binds to the
invariant catalytic nucleophile Glu441, in an active site pocket
on the enzyme surface. The active site pocket is freely
accessible to solvent, with little steric hindrance for tagged,
functionalized aziridines such as 4 (Supplementary Figure 4a).
Binding of tagged ABP 4 to both GBA2 and TxGH116 can also
be directly observed by ﬂuorescent scanning of the respective
proteins after ABP labeling (Figure 1A and Supplementary
Figure 4B).
FluoPol-ABPP studies that have appeared in the literature
make use of the tetramethylrhodamine (TMR) dye.15 In order
to stay in tune with these studies, we therefore synthesized
TMR-cyclophellitol aziridine 4 (for synthesis details see the
Supporting Information, SI Schemes 1 and 2). GBA2 was stably
overexpressed in HEK293 cells, constituting the majority of all
β-glucosidase activity (the ratio of GBA2 levels over other
targets labeled by 4 was established by prolonged imaging of
the gel shown in Figure 1A; see the Supporting Information, SI
Figure S1). Extracts of HEK293 overexpressing GBA2 were
Figure 1. (A) Screening for GBA2 inhibitors (e.g., 1, 2, or 3) using
activity-based probe 4 as a read-out in a FluoPol-ABPP assay. (B) 3-D
structure (PDB 5NCX) of the TxGH116 β-glucosidase bound to
cyclophellitol aziridine 5; the enzymatic nucleophile Glu441 and
putative acid/base Asp593 are shown for reference. The map shown is
a maximum-likelihood weighted 2Fobs − Fcalc at 0.4 e−/Å3.
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treated with ABP 4 at 500 nM at pH 7, and the protein content
was resolved by SDS PAGE. Fluorescence scanning of the wet
gel slab (λex 530 nm, λem 580 nm, Figure 1A) revealed a major
band at about 102 kDa, which corresponds to the molecular
weight of mature GBA2. Levels of active GBA2 in the
overexpressing cells are such that endogenous GBA and
GBA3, which are also targets of cyclophellitol aziridine ABPs,
are hardly visible, even though labeling of GBA and GBA3 is
saturating at the probe concentrations used. GBA2 labeling
with 4 can be abolished by preincubation with the known
GBA2 inhibitors Zavesca (1) (100 μM ﬁnal concentration) and
AMP-DNM (2) (10 μM ﬁnal concentration) in a competitive
ABPP experiment (Figure 1A, lanes 2 and 3, respectively). In
ﬂuorescence polarization assays, a ﬂuorophore is excited at a
speciﬁc wavelength with linear polarized light. The orientation
of emitted light and thereby the degree of polarized light
depend on the movement the excited ﬂuorophore has
undergone, which depends on its size: large molecules (such
as GBA2-bound 4) move and rotate slower than small
molecules (here: free 4). Samples are irradiated with linear
polarized light (λex 530 nm), and the degree of loss of polarized
light emitted at λem 580 nm represents the degree of inhibition
of GBA2 labeling with 4. Initial experiments using ﬂuorescence
polarization as a read-out were performed in 96-well plates. The
pH optimum of GBA2 is reported1 to be at pH 5.8, and
contemporary assays for measuring GBA2 inhibitor activities
are performed at or close to this pH. We (Figure 2A)
established that, in a range from pH 4 to pH 8 (the range at
which GBA2 possesses measurable activity), maximal return of
polarized light occurs at pH 7. The optimal ﬁnal probe
concentration in the assay conditions used (protein concen-
tration 0.5 mg/mL, Vfinal 75 μL), which intrinsically depends on
the amount of active GBA2 present in the extracts (which we
keep constant), was found to be 25−50 nM (Figure 2B); in this
setting a suitable diﬀerence in polarized light emission (Δ about
180 mPol) was achieved between samples derived from GBA2-
overexpressing cells and wild-type cells. IC50 values of a set of
known GBA2 inhibitors, both competitive (Zavesca (1), AMP-
DNM (2), L-ido-AMP-DNM (6), DNM (7)) and mechanism-
based (cyclophellitol, 8), were next established using the
FluoPol-ABPP format using 50 nM ABP 4. Values obtained
(Figure 2D) were in line with literature values on the same
compound, for both the potent (2, 3, 6) and less potent (1, 7,
8), which were all established using ﬂuorogenic substrate
assays, thereby validating our FluoPol-ABPP assay.16
We next transferred our assay to a 384-well plate format
(Vfinal 15 μL) and screened our complete iminosugar library,
containing both previously published and until now unpub-
lished compounds (the structures of all 358 compounds and
the synthesis of new compounds are in the Supporting
Information). All compounds were assessed at 100 nM ﬁnal
concentration, and the percentage of GBA2 inhibition
calculated from the relative loss of ﬂuorescence polarization
was observed. Besides N-alkyldeoxynojirimycin, the corre-
sponding D-galacto- and L-ido-conﬁgured iminosugars are
known to be potent GBA2 inhibitors, and library entries
adhering to this general description are picked up in our
FluoPol-ABPP assay as well (Figure 3).16 Alternatively
conﬁgured piperidines, partially deoxygenated deoxynojirimycin
derivatives, and hydroxylated pyrrolidines show up only rarely,
if at all, as inhibitors in our assays (for a more detailed grouping
of compound classes and GBA2 inhibition see the Supporting
Information).
Among the most potent GBA2 inhibitors we identiﬁed
neopentyloxypentyl-deoxynojirimycin 9 and its L-ido-congener
10 (Figure 3). Intriguingly, for these compounds the
hydrophobic N-alkyl group is relatively small compared to
that of 2 and 3. We previously found that large (as in 2) and
preferably aromatic (as in 3) alkoxy substituents are preferred
by GCS and reasoned that a reduced size of this part of the
molecule may be favorable for achieving GBA2 selectivity over
the ceramide glucosyltransferase. Accordingly, we synthesized a
set of close analogues of compounds 9 and 10 and assessed
their inhibitory potency against GBA2, GBA, GBA3, and GCS
(examples of second-generation library 11−15 in Figure 3; for
Figure 2. Optimization and validation of FluoPol-ABPP for GBA2.
(A) Eﬀect of pH. (B) Eﬀect of probe concentration. (C) Structures of
additional established inhibitors. (D) Inhibition by established
inhibitors (1, 2, 6, 7, and 8). Error bars represent standard error of
the mean (SEM).
Figure 3. FluoPol-ABPP assay with an iminosugar library (358
entries). (A) Competition at 100 nM. (B) Examples of second-
generation analogues of compounds 9 and 10.
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synthesis and analytical details see the Supporting Informa-
tion).
As can be seen in Table 1, compounds 9 and 10 are highly
potent and rather selective GBA2 inhibitors. Removal of one
methyl group, as in isopropyl derivatives 11 and 12, led to an
increase of inhibitory potency against GBA2 with concomitant
(slight) decrease of inhibitory potency against GCS. L-ido-
conﬁgured compounds 10 and 12 are over 100 000-fold
selective for GBA2 over GBA1, which is a signiﬁcant
improvement compared to previously reported inhibitors
showing a maximal 10 000-fold selectivity (for selectivity ratios
of the compounds in Table 1 for GBA2 oﬀset against GBA,
GBA3, and GCS, respectively, see the Supporting Information,
SI 8). As mentioned earlier, the activity against GCS is much
reduced when comparing to our previously reported adamantyl
and biphenyl compounds, respectively 2 and 3. Compounds 9,
13, and 14 are about 1000-fold more potent on GBA2 over
GCS, while previously reported compounds are at best 150-fold
more selective. While substitution of the neopentyl moiety for
tetrahydrofuranylmethyl groups, as in 14 and 15, had a
detrimental eﬀect on inhibitory potency toward GBA, GBA2,
and GCS, it has no signiﬁcant eﬀect on the selectivity. Based on
both potency and selectivity, neopentyl and isopropyl
derivatives 9−12 are perhaps the most potent and selective
GBA2 inhibitors reported to date.
In a ﬁnal in situ target engagement experiment we performed
competitive ABPP on live cells. Cells overexpressing GBA2 or
GBA3 and containing endogenous GBA levels were treated
with compounds 9−12 at various ﬁnal concentrations, lysed,
and then treated with ABP 4. As can be seen from the images of
the SDS PAGE gels (Figure 4), all compounds are cell
permeable and selectively block GBA2 over GBA and GBA3 at
the concentrations tested.
■ CONCLUSIONS
Collectively, this work describes the development of an
eﬀective FluoPol-ABPP assay for the rapid screening of
GBA2 inhibitors. Fluorescence polarization (FluoPol) is often
used for the analysis of the potency of small molecules to
inhibit enzymes17 but has to the best of our knowledge not
been used in the context of glycosidase inhibitor assays. This
certainly holds true for the combination of FluoPol and
ABPP,18 as we show here. FluoPol-ABPP can be conducted on
target enzymes in complex mixtures, as long as the ABP used
modiﬁes with considerable selectivity the target enzyme. This
can be achieved even with broad-spectrum ABPs such as the
one used here, simply by bringing the target enzyme to
overexpression. Target selectivity is easily established by
running an SDS PAGE on the ABP-labeled sample. One
potential caveat of FluoPol-ABPP is the covalent and
irreversible nature of the ABP used. Most studies on FluoPol-
ABPP inhibitor screening entail the assessment of covalent
inhibitors.18 Here, we show that competitive inhibitors can also
be identiﬁed using FluoPol-ABPP as an initial screen, after
which more in-depth kinetic studies can be executed on
selected compounds using conventional assays using ﬂuoro-
genic substrates. Here, we identiﬁed a few compounds from our
358-compound collection that possess considerable GBA2
selectivity, and on the basis of these lead structures we prepared
a small focused library to add to our growing library of
iminosugar glycosidase inhibitors. In-depth analysis revealed
that, indeed, modulating the size of the hydrophobic nitrogen
substituent yields inhibitors more potent, and crucially also
more selective, for GBA2 compared to existing inhibitors. From
a technical point of view, the FluoPol-ABPP assay can be
adapted to allow high-throughput screening of large compound
selections on GBA2 inhibition. Conceptually, with this study
we show that FluoPol-ABPP, as a recently proposed strategy for
high-throughput screening of various enzymes, is also
eminently feasible for searching for glycosidase inhibitors,
especially considering that the list of activity-based glycosidase
probes targeting a variety of retaining glycosidases is growing.
Table 1. Inhibition Values and Selectivity Ratios of Deoxynojirimycin Derivatives on GCS, GBA, GBA2, and GBA3
compound GCSa GBA1b GBA2b GBA3b GCS/GBA2c GBA1/GBA2c GBA3/GBA2c
1 50 675 0.326 >1000 153 2071 >3067
2 0.15 0.28 0.0035 27.6 43 80 7886
3 0.008 25.3 0.0027 27.8 3 9370 10296
6 0.15 12.4 0.0083 66.1 18 1494 7964
9 5.05 3.8 0.0051 27.6 990 745 5412
10 2.77 120 0.0077 119 360 15584 15455
11 3.87 10.8 0.0075 128 516 1440 17067
12 0.729 1223 0.0095 177 77 128737 18632
13 6 7.3 0.0059 116 1017 1237 19661
14 53 92 0.0536 180 989 1716 3358
15 >50 122 0.1771 145 >282 689 819
aInhibition value for in situ assay is given as IC50 (μM).
bInhibition value for in vitro assay is given as Ki (μM).
cRelative GBA2 oﬀset (ratio)
Figure 4. Competitive ABPP experiment of HEK293T cells
overexpressing GBA2 or GBA3 (and expressing endogenous GBA)
treated with compounds 9−12 at various ﬁnal concentrations prior to
cell lysis and ABPP proﬁling of remaining enzyme activity.
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■ EXPERIMENTAL SECTION
Cell Culture. Human embryonic kidney 293T (HEK293T) cells
(Sigma) were cultured in DMEM high glucose (Gibco) supplemented
with 10% NBS and 100 units/mL penicillin/streptomycin (Gibco) at
37 °C and 5% CO2. RAW 264.7 cells (American Type Culture
Collection) were cultured in RPMI (Gibco) supplemented with 10%
fetal calf serum, 1 mM Glutamax, and 100 units/mL penicillin/
streptomycin (Gibco) at 37 °C and 5% CO2.
Transient and Stable Overexpression of Human GBA2 and
GBA3. Primers used for transient GBA2-expressing HEK293T were
designed based on NCBI reference sequence NM_020944.2. The full-
length coding sequences were cloned into pcDNA3.1/Myc-His
(Invitrogen, Life Technologies, Carlsbad, CA, USA). Subconﬂuent
HEK293T cells were transfected with empty pcDNA3.1 or
GBA2pcDNA3.1 (plasmid:PEI ratio 1:3). Media was refreshed 24 h
later, and cells were collected 72 h after transfection in phosphate-
buﬀered saline (PBS) buﬀer. Cells were centrifuged at 1000 rpm for 10
min, after which the supernatant was removed. Cell pellets were snap-
frozen with liquid nitrogen and stored at −80 °C.
Stable GBA2-expressing HEK293T cells were generated as follows.
The PCR-ampliﬁed human GBA2 (GBA2, acc. no. NM_020944.2)
coding sequence (using the following primers: sense 5′-GGGGACAA-
GTTTGTACA AAAAAGCAGGCTTAACCACCATGGGGACCC-
AGGAT CCAG-3′ and antisense 5′- GGGGACCACTTTGTAC
AAGAAAGCTGGGTTTCACTCTGGGCTCAGGTTTG-3′) was
cloned into pDNOR-221 and subcloned in pLenti6.3/TO/V5-DEST
using the Gateway system (Invitrogen). Correctness of the construct
was veriﬁed by sequencing. HEK293T cells were transfected with
pLenti6.3-GBA2 in combination with the envelope and packaging
plasmids pMD2G, pRRE, and pRSV. Subsequently, culture super-
natant containing viral particles was collected and used for infection of
HEK293T cells. Selection using blasticidin for several weeks rendered
cells stably expressing human GBA2 as determined by activity assays.
For stable expression of GBA3 in HEK293T cells, the PCR-ampliﬁed
GBA3 (GBA3, acc. no. NM_020973.4) coding sequence (using the
following oligonucleotides: sense 5′-GAATTCGCCGCACCAT-
GGCTTTCCCTGCAGGATTTG-3′ and antisense 5′-GCGGCCGC-
AGATGTGCTTCAA GGCCATTG-3′) was cloned into pcDNA3.1/
Zeo and transfected into HEK293T cells using FuGene 6 Transfection
Reagent (Promega Benelux, Leiden, The Netherlands). Selection using
Zeocin for several weeks rendered cells stably expressing human GBA3
as determined by activity assays.
Preparation of Lysates. Cell pellets were resuspended in lysis
buﬀer (20 mM hepes, 2 mM DTT, 0.25 M sucrose, 1 mM MgCl2, 2.5
U/mL benzonase, pH 7.0). The homogenate was incubated on ice for
30 min after lysis and homogenization using SilentCrusher
(Heidolph). Ultracentrifugation was performed at 32.000 rpm for 30
min at 4 °C. Supernatant fractions were aliquoted in appropriate
volumes, after the total protein concentration was determined via a
Bradford assay, using BSA (Sigma) for standards and BioRad
Quickstart Bradford Reagents. Aliquots were snap-frozen with liquid
nitrogen and stored at −80 °C.
Gel-Activity-Based Protein Proﬁling Experiments. Prepared
lysate was diluted in assay buﬀer (20 mM Hepes, 2 mM DTT at pH
7.0) until appropriate ﬁnal protein concentration was reached. Samples
were incubated with 500 nM probe at 37 °C for 1 h (Vfinal = 20 μL).
Protein content was denatured using Laemli buﬀer (4×) at 100 °C for
3 min. Reactions were resolved by 12.5% SDS-PAGE electrophoresis,
and wet slabs were scanned for ﬂuorescence (Molecular Imager Gel
Doc XR, Biorad). For the in situ competitive ABPP experiments stable
GBA2- and GBA3-overexpressing HEK293T cells were incubated for 1
h at 37 °C with various concentrations of the selected inhibitors. Cells
were washed two times with PBS and then harvested by scraping in 25
mM potassium phosphate buﬀer (pH 6.5) containing 0.1% Triton X-
100 (v/v). Cells were lysed via snap-freezing in liquid nitrogen. Protein
concentration was determined via BCA assay (Thermo Fischer).
Labeling of the glucosidases was conducted using 500 nM ABP 4 for
30 min at 37 °C on 20 μg of protein. Protein content was denatured
using Laemli buﬀer (5×) at 100 °C for 5 min. Reactions were resolved
by 10% SDS-PAGE electrophoresis, and wet slabs were scanned as
described above.
Optimization of the FluoPol-ABPP Assay. Optimal probe
concentration on the FluoPol signal was determined by varying probe
concentrations from 25 to 500 nM probe at a constant lysate
concentration (0.5 mg/mL) and neutral pH. FluoPol-ABPP assays
were also performed at diﬀerent pH values. Hepes was replaced by 20
mM citric acid−citrate buﬀer for reactions at pH ≤ 6. The pH
experiments were performed at optimal probe concentration (50 nM).
Competition experiments were conducted by 30 min of preincubation
of compounds in the lysates at 37 °C (2.5% DMSO). All reactions
(Vfinal 75 μL) containing bovine gamma-globulin (Sigma) and Chaps
(Sigma), respectively 0.5 and 1 mg/mL, were carried out in 96-well
plates (ﬂat-black bottom, Greiner). FluoPol signals were monitored on
an Inﬁnite M1000Pro (Tecan) using λex 530 nm and λem 580 nm.
Mock-containing lysates were used as reference samples, samples
without probe as blanks to correct for background polarization, and
GBA2-containing lysates without inhibitor as controls. All samples
were corrected for background polarization, and the residual enzyme
activity was calculated based on the polarization signal from the
controls. Polarization signals were plotted against time or inhibitor
concentration and processed in GraphPad Prism 6.0. IC50 values were
calculated via nonlinear regression using the mentioned software (N =
2, n = 3).
FluoPol-ABPP Screen of the Iminosugar Library. The screen,
using the optimized conditions as described above, was conducted in a
384-well black-bottom plate (Greiner) with reaction volumes set at 15
μL. Concentration of the iminosugars during the screen was 100 nM.
The FluoPol signal was measured on a PHERAstar (BMG Labtech).
Resulting polarization signals were processed as described above.
Residual enzyme activities were plotted against the corresponding
iminosugar.
Analysis of Selected Compounds as Inhibitors of Enzymatic
Activity of GCS, GBA, GBA2, and GBA3. Enzyme assays of GCS,
GBA1, GBA2, and GBA3 were carried out as previously described
(refs 16 and 19), and inhibition by selected compounds was assessed.
Brieﬂy, for GBA1, pure recombinant human enzyme (Cerezyme from
Genzyme) was used. Activity was measured with 3.7 mM 4-
methylumbeliferone (4MU)-β-D-glucopyranoside (Sigma) in 150
mM McIlvaine buﬀer pH 5.2 supplemented with 0.2% sodium
taurocholate (w/v), 0.1% Triton X-100 (v/v), and 0.1% bovine serum
albumin (BSA) (w/v) for 30 min. The reaction was stopped with
excess 1 M NaOH-glycine (pH 10.3), and liberated 4MU ﬂuorescence
was measured with an LS55 ﬂuorimeter (PerkinElmer) using λEx 366
nm and λEm 445 nm. For GBA2 measurements, cellular homogenates
of a stable HEK293T-overexpressing GBA2 cell line preincubated for
30 min with an inhibitor of GBA1 (1 mM conduritol β epoxide CBE
from Sigma) were used. Activity was measured with 3.7 mM 4MU-β-D-
glucopyranoside in 150 mM McIlvaine pH 5.8 and 0.1% BSA (w/v)
for 1 h. Reactions were stopped as described above for GBA1. For
GBA3 measurements, cellular homogenates of a stable HEK293T-
overexpressing GBA3 cell line also preincubated for 30 min with an
inhibitor of GBA1 (1 mM conduritol β epoxide CBE from Sigma)
were used. Reactions were conducted in 100 mM hepes pH 7.0 and
0.1% BSA (w/v) for 1 h. All IC50 values were determined in triplicate,
and the inhibitors tested were preincubated for 30 min at 37 °C. Ki
values were determined in duplicate using a range from 0.05 to 5 mM
4MU-β-D-glucopyranoside in appropriate buﬀer containing inhibitor.
Incubation time and temperature were the same as described above,
but without the preincubation step. Observed ﬂuorescence was curve-
ﬁtted against inhibitor or substrate concentrations using GraphPad
Prism 6.0 in order to obtain IC50 or Ki values.
IC50 values for GCS were determined in situ with 6-[N-methyl-N-
(7-nitrobenz-2-oxa-1,3-diazol-4-ylaminododecanoyl]sphingosine
(NBD-ceramide) as substrate. RAW 264.7 cells were grown to
conﬂuence in six-well plates and preincubated for 1 h with an inhibitor
of GBA1 activity (300 μM CBE), followed by 1 h incubation at 37 °C
with 1 μM C6-NBD-ceramide and in the presence of a range of
inhibitor concentrations. The cells were washed 3× with PBS and
harvested by scraping. After lipid extraction (described by Bligh and
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Dyer20), the C6-NBD lipids were separated and detected by high-
performance liquid chromatography (λEx 470 nm and λEm 530 nm).
IC50 values were determined in duplicate from the titration curves of
observed formed C6-NBD-glucosylceramide, and data were curve-
ﬁtted via GraphPad Prism 6.0.
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